Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Management of Coronary Artery Disease from Late Kawasaki Disease
Author(s): Khung Keong Yeo , Ryuji Fukazawa , Mamoru Ayusawa , et al Added: 1 year ago

Vascular Disease and Surgery

Guidelines & Statements
TCT Middle East 25: Evaluating CAD
Author(s): Nouf Alanazi , Alaide Chieffo , Added: 2 months ago
TCT Middle East 2025 — We are joined by Dr Nouf Alanazi, Dr Alaide Chieffo and Dr Nadia Sutton as they discuss key takeaways from the conference for the physiological assessment of coronary artery disease.The panel explores emerging paradigms in MINOCA and INOCA management, addressing the limitations of conventional approaches. They review current guideline recommendations for functional testing… View more

Guidelines & Statements

Intervention
Calcium Modification Techniques for Coronary Artery Disease
Author(s): Rodrigo Bagur , Angela McInerney , Rolf Kreutz , et al Start date: Apr 23, 2025
This webinar brings together leading experts Dr Rodrigo Bagur, Dr Angela McInerney, Dr Rolf Kreutz, Dr Sohail Khan, Dr Sophia Khattak, Dr Jonathan Hinton and Dr Peter O’Kane to explore the challenges and solutions in managing calcified coronary artery disease. The session will provide a detailed examination of coronary calcification from pathological and clinical perspectives, including… View more

Intervention
ESC 24: EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD
Author(s): Gi-Byoung Nam , Min Soo Cho Added: 10 months ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study… View more

Anticoagulation

Electrophysiology & Arrhythmia
EuroPCR 24: Influence of Pathophysiological Patterns of CAD on PCI
Author(s): Carlos Collet Added: 1 year ago
EuroPCR 24 - We are joined onsite by Dr Carlos Collet (OLV Hospital Aalst, BE) to discuss the findings from a study analysing the influences of the pathophysiological patterns of coronary artery disease on the safety and efficacy of PCI.The study aimed to assess the capacity of pullback pressure gradient (PPG) in predicting post-PCI fractional flow ratio (FFR), as well as the impact of PPG on… View more

Intervention
ACC 25: The EKSTROM Trial
Author(s): Matthew J Budoff Added: 3 months ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical… View more

Intervention
ESC HFA 25: SCD-PROTECT
Author(s): Johann Bauersachs Added: 1 month ago
ESC HF 25 - SCD-PROTECT shows high risk of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) during early medical therapy optimization for reduced LVEF in patients with new non-ischemic cardiomyopathy or MI/CAD.Prof Johann Bauersachs (Hannover Medical School, Hannover, DE) discusses findings from the SCD–PROTECT study, an investigation of sudden cardiac arrest in patients with newly… View more

Heart Failure

MI/ACS
AHA 23: The ORFAN Study
Author(s): Charalambos Antoniades Added: 1 year ago
AHA 23 — In this brief interview, we are joined by Prof Charalambos Antoniades (Oxford University, UK) to discuss the ORFAN trial, sponsored by the University of Oxford.ORFAN is a prospective, multicenter, observational study that collected CT scans, biological material and outcomes data to develop and validate biomarkers of cardiometabolic risk. The registry included 250000 unselected… View more

Digital Health

Prevention & Chronic Conditions
ESC 23: LODESTAR Trial
Author(s): Myeong-Ki Hong Added: 1 year ago
ESC 23 — Dr Myeong-Ki Hong (Yonsei University College of Medicine, KR) outlines the late-breaking results from the LODESTAR trial (NCT02579499). LODESTAR (Yonsei University) was a randomized, open-label multicenter trial that aimed to compare the clinical efficacy and safety of atorvastatin vs rosuvastatin for the secondary prevention of coronary artery disease. 4400 coronary artery disease… View more

Prevention & Chronic Conditions
Detection and Stabilisation of Vulnerable Plaques in the Coronary Arteries
Author(s): Guzel Bikbaeva , Anna Kovalskaya , Alexander Rodin , et al Added: 1 year ago

Imaging & Diagnostics

Prevention & Chronic Conditions